Blackhawk Update

Blackhawk Update

(TheNewswire)

This press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues.

Vancouver, British Columbia TheNewswire - August 26, 2025 Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Company" or "Blackhawk") this news release is being disseminated according to National Instrument 62-103, The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, in connection with the sale of common shares (the "Common Shares") of Blackhawk Growth Corp. (the "Issuer"), whose common shares are listed for trading on the Canadian Securities Exchange.

Between August 19 and 21, 2025 Shape Capital (Seller) sold 10,000,000 Common Shares of the Issuer at a price of $0.05 per Common Share. This sale being the date of the last early warning report filed by the Seller with respect to the Issuer, resulted in a change in the Sellers holdings in the Common Shares of the Issuer from 11.33% to 0%.

The Form 62-103F1 – Required Disclosure under the Early Warning Requirements associated with this news release can be obtained from SEDAR+ at www.sedarplus.ca . In the alternate, to obtain a copy of the report, please contact Anoosh Manzoori at +61.3.966 6338

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies.

For further information please contact:

Justin Hanka, Chief Executive Officer

+61.433140886

justin@blackhawkgrowthcorp.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

BLR:CNX
The Conversation (0)
Blackhawk Growth Corp.

Blackhawk Growth Corp.

Blackhawk Growth Corp is an investment issuer looking to capitalize on market and industry trends that can create substantial value for its shareholders. The company invests in equity and debt instruments of companies to generate positive returns for shareholders.

Blackhawk Growth Corp Advances Human Clinical Trials in Asthmatic AI Technology

Blackhawk Growth Corp Advances Human Clinical Trials in Asthmatic AI Technology

Blackhawk Growth Corp. (CSE:BLR)(Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to provide an update on Hardenbrook portfolio company - Asthmatic AI

We are pleased to report that Asthmatic AI, a Hardenbrook and Life AI Corp asset (https://www.lifeaicorp.com) has completed 50 participants in human clinical trials and is now working on the next 250 participants as it develops its Asthma attack prediction technology for use in the clinical management of Asthma.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Update on the Acquisition of Hardenbrook Group

Update on the Acquisition of Hardenbrook Group

(TheNewswire)

Vancouver, British Columbia April 15, 2024 TheNewswire Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the " Company " or " Blackhawk "), is pleased to provide an update on the proposed acquisition of Hardenbrook Group Pty Ltd. (" Hardenbrook ")

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×